Public Release: 

Consensus by international federation on drug use at high altitude

Mary Ann Liebert, Inc./Genetic Engineering News



High Altitude Medicine & Biology, the Official Journal of the International Society for Mountain Medicine, is published quarterly online. It is the only peer-reviewed journal dedicated exclusively to... view more

Credit: ©Mary Ann Liebert, Inc., publishers

New Rochelle, NY, October 25, 2016 - Drug taking at high altitude is variably intended to enhance performance, prevent or alleviate the debilitating effects of altitude, or for pleasurable use. In some cases, certain drugs can be advantageous and even life-saving, but many drugs lack evidence of benefit and carry risks of side effects or interactions. The International Climbing and Mountaineering Federation (UIAA) has published evidence-based guidelines advising on the safe use of alcohol, steroids, oxygen, erythropoietin, and many other types of drugs in mountain environments in an article in High Altitude Medicine & Biology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free online on the High Altitude Medicine & Biology website.

An international team of researchers from Kuwait, Austria, United Kingdom, Germany, Switzerland, Nepal, Spain, France, and the Netherlands, led by David Hillebrandt, MB, BS, President, UIAA Medical Commission, coauthored the article entitled "Drug Use and Misuse in the Mountains. An UIAA MedCom-Consensus Guide for Medical Professionals." They conducted an extensive review of the medical literature, trials, observational studies, and case series to assess the evidence available for drugs commonly used by mountain climbers. Their conclusions and recommendations cover a broad range of drug types including alcohol, anabolic agents such as androgenic steroids, adrenergic agonists, beta-blocking agents, erythropoietin, oxygen, glucocorticosteroids, benzodiazepines, and stimulants such as amphetamines.

"The use of drugs beyond those proven effective in preventing and treating high altitude illnesses remains very controversial among both physicians and climbers," says Erik R. Swenson, MD, Editor-in-Chief of High Altitude Medicine & Biology and Professor, Division of Pulmonary and Critical Care Medicine, Veterans Administration Puget Sound Healthcare System. "This broad and comprehensive review of the myriad drugs used for various purposes in climbing will be useful to all concerned in decision-making about their use, determining the level of supportive evidence, and importantly their potential costs and adverse effects."


About the Journal

High Altitude Medicine & Biology, the Official Journal of the International Society for Mountain Medicine, is published quarterly online. It is the only peer-reviewed journal dedicated exclusively to the latest advances in high altitude life sciences. The journal presents findings on the effects of chronic hypoxia on lung and heart disease, pulmonary and cerebral edema, hypertension, dehydration, infertility, appetite and weight loss, and other diseases. Complete tables of content and sample issue may be viewed online at the High Altitude Medicine & Biology website.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Journal of Aerosol Medicine and Pulmonary Drug Delivery, and Pediatric Allergy, Immunology, and Pulmonology. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available at the Mary Ann Liebert, Inc., publishers website.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.